

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*Complete if Known*

Application Number	10/595,399
Nat. Phase Filing Date	April 13, 2006
First Named Inventor	Salama
Group Art Unit	
Examiner Name	

Sheet	1		3	Attorney Docket Number	7014.120
-------	---	--	---	------------------------	----------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
		4,119,653		TOBE MARTIN LESLIE ET AL.	10-10-1978

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
		WO	03/066526		IMMCONT GMBH & KG PHARMOPLATIN; MELNIKOV MIKHAIL YAKOVLEVICH	08-14-2003	ABSTRACT
		EP	0339772		JOHNSON MATTHEY PLC	11-02-1989	
		RU	2086261		UNIV MOSC LOMONOSOV CHEM FACULTY	08-10-1997	ABSTRACT
		DE	2004/002297		SALAMA	04-05-2005	
			International Search Report				
Examiner Signature		/Tristan J. Mahyera/			Date Considered	10/14/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.M./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 			<i>Complete if Known</i>		
			Application Number	10/595,399	
			Nat. Phase Filing Date	April 13, 2006	
			First Named Inventor	Salama	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	3	Attorney Docket Number	7012.120
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
		Database WPI, Section CH, Week 199815, Derwent Publications Ltd., London, GB; Class B05, AN 1998-167679.			
		Tobe, M.L., et al., "Structure, activity, reactivity and solubility relationships of platinum diamine complexes", J.CLIN.HEMATOL.ONCOL. 1977, vol. 7, no. 1, 1977, pp 114-137.			
		Presnov, M.A., et al., "The antitumor activity of oxoplatinum", NEOPLASMA (1985), 32(1), pp 73-83, 1985.			
		Presnov, M.A., et al., "Antitumor properties of cis-dichlorodiamminedihydroxyplatinum(IV)", IZVESTIYA AKADEMII NAUK SSSR, SERIYA BIOLOGICHESKAYA (1986), (3), PP 417-28, 1986.			ABSTRACT
		Orr, R.M., et al., "Evaluation of novel platinum (II), and platinum (IV) ammine/amine complexes in L1210 murine leukemia cell lines sensitive and resistant to cisplatin and tetraplatin", CELLULAR PHARMACOLOGY (1993), 1(1), pp 17-23, 1993.			
		Brandon, R.J., et al., "Synthesis, characterization, and properties of a group of platinum (IV) complexes.", JOURNAL OF MEDICINAL CHEMISTRY. UNITED STATES JUL 1984, vol. 27, no. 7, July 1984, pp 861-865.			
		Presnov, M.A., et al., "Cycloplatin and oxoplatin – the new antitumor platinum compounds of the second generation", ARCHIV FUER GESCHWULSTFORSCHUNG (1988), 58(1) pp 43-9, 1988.			
		Kelland, L.R., et al., "Structure-activity relationships in a series of novel platinum(II) and platinum(IV) ammine-amine complexes evaluated against a panel of human ovarian carcinoma cell lines", JOURNAL OF CELLULAR PHARMACOLOGY (1992), 2(6), pp 331-42.			
		Keprtova, J., et al., "The effect of second generation platinum cytostatics on mammalian cell proliferation.", NEOPLASMA. CZECHOSLOVAKIA 1990, vol. 37, no. 2, 1990, pp 121-129.			
		Blatter, E.E., et al., "Interaction of the antitumor agents cis,cis,trans-PtIV(NH3)2C12(OH)2 and cis,cis,trans-PtIV(CH3)2CHNH2I2C12(OH)2 and their reduction products with PM2 DNA.", BIOCHEMISTRY. UNITED STATES 9 OCT 1984, vol. 23, no. 21, 9 October 1984, pp 4817-4820.			
		Kononova, A.I., et al., "Antineoplastic effect of complex platinum(IV) compounds", DOKLADY AKADEMII NAUK SSSR (1977), 234(1), pp 223-6 'BIOCHEM.I., 1977.			
		Yen, Tran Cong, et al., "Study on potential of prolongation of survival in mice with cancers (before and after amputation) treated with cis-dichlorodiamine trans-dihydroxo platinum(IV)", TAP CHI DUOC HOC (2001), (2), pp 19-21, 2001.			SUMMARY
		Tran, Cong Yen, et al., "Action of platinum(IV) complexes on sarcoma TG-180 cells in vivo", TAP CHI DUOC HOC (1998), (6), pp 18-20, 1998.			SUMMARY
Examiner Signature	/Tristan J. Mahyera/			Date Considered	10/14/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.M./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	10/595,399
				Nat. Phase Filing Date	April 13, 2006
				First Named Inventor	Salama
				Group Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	7012.120
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
		Nguyen, Thi Quy, et al., "The antitumor effectiveness of a platinum(IV) compound in Swiss mice", TAP CHI DUOC HOC (1998), (3), pp 21-23, 1998.			SUMMARY
		Arefeva, A.K., et al., "Antitumor effectiveness and nephrotoxicity of oxoplatinum!" VOPROSY ONKOLOGII. USSR 1990, vol. 36, no. 3, 1990, pp 331-334.			ABSTRACT
		Kelland, L.R., et al., "A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.", CANCER RESEARCH. UNITED STATES 1 NOV 1994, vol. 54, no. 21, 1 November 1994, pp 5618-5622.			
		Vollano, J.F., et al., "DNA breakage by a perhydrate complex of cis,cis,trans-PtIVCL2(NH3)2(OH)2", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, XX, vol. 106, no. 9, 1984, pp 2732-2733.			
		Novakova, Olga, et al., "DNA interactions of antitumor platinum(IV) complexes", EUROPEAN JOURNAL OF BIOCHEMISTRY (1995), 228(3), pp 616-24, 1995.			
		Brabec, V., et al., "Tetravalent platinum complexes can exert their antitumor effect via direct reaction with DNA", STUDIA BIOPHYSICA, vol. 114, no. 1-3, 1986, pp 199-207.			
		Gutsche, W., et al., "Structure-activity relationships of active antineoplastic platinum(II) and (IV) coordination compounds", ARCHIV FUER GESCHWULSTFORSCHUNG (1989), 59(4), pp 233-8, 1989.			ABSTRACT
		Giandomenico, C.M., et al., "Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entree into orally active platinum(IV) antitumor agents", METAL CONSTRUCTION, CAMBRIDGE, GB, vol. 34, 1995, pp 1015-1021.			
Examiner Signature	/Tristan J. Mahyera/			Date Considered	10/14/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.M./